Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17787143 | 0.79 | AAK1 (0.39) | ROCK2AKT1 | |
| SCHEMBL1492665 | 0.77 | APP (0.45) | ROCK2NR3C1IMPDH2 | |
| SCHEMBL31584143 | 0.77 | CTSB (0.46) | ROCK2ROCK1AKT1IMPDH2 | |
| SCHEMBL13802935 | 0.77 | AAK1 (0.41) | ROCK2NR3C1GABRB1GABRB2 | |
| SCHEMBL28206157 | 0.76 | ROCK2 (0.44) | ROCK2ROCK1NR3C1IMPDH2 | |
| SCHEMBL24502886 | 0.74 | CTSS (0.53) | ROCK2 | |
| SCHEMBL31584094 | 0.74 | CTSS (0.53) | ROCK2 | |
| SCHEMBL31584126 | 0.74 | CTSS (0.45) | ROCK2AKT1IMPDH2 | |
| SCHEMBL1105145 | 0.74 | ROCK2 (0.60) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL23453276 | 0.73 | IMPDH2 (0.50) | ROCK2ROCK1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-05-19 | — | — | US | disclosed |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-08 | — | — | US | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-05-23 | — | — | US | disclosed |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-03-05 | — | — | US | disclosed |
| EP-3033332-B1 | BICYCLIC PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-09-19 | — | — | EP | disclosed |
| EP-3033336-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2018-05-30 | — | — | EP | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-9738641-B2 | Bicyclic inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-20160185773-A1 | BICYCLIC INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| EP-3033332-A1 | BICYCLIC INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2016-06-22 | — | — | EP | disclosed |
| EP-3033336-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2016-06-22 | — | — | EP | disclosed |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| WO-2016083816-A1 | N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| EP-2999697-A1 | HETEROCYCLIC DERIVATES | Kalvista Pharmaceuticals Limited (GB) | 2016-03-30 | — | — | EP | disclosed |
| WO-2015022547-A1 | BICYCLIC INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015022546-A1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-02-19 | — | — | WO | disclosed |
| WO-2014188211-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152950-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | ROCK2 1107/4885ROCK1 975/4885NR3C1 2714/4885 |
| US-20220153724-A1 | Inhibitors Of Plasma Kallikrein | KLKB1, SERPINB1, KLK5 | ROCK2 1107/4885ROCK1 975/4885NR3C1 2714/4885 |
| US-11242333-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | ROCK2 1107/4885ROCK1 975/4885NR3C1 2714/4885 |
| US-10221161-B2 | Inhibitors of plasma kallikrein | KLKB1, SERPINB1, KLK5 | ROCK2 1107/4885ROCK1 975/4885NR3C1 2714/4885 |
| US-20160185773-A1 | BICYCLIC INHIBITORS | KLKB1, SERPINB1, BDKRB1 | ROCK2 2744/4885ROCK1 2159/4885NR3C1 1668/4885 |
| US-20160168123-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, SERPINB1, KLK5 | ROCK2 1107/4885ROCK1 975/4885NR3C1 2714/4885 |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | ROCK2 1618/4885ROCK1 839/4885NR3C1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.